Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Medite Cancer Diagnostics, Inc. (MDIT)
Orlando, FL, US
Medite Cancer Diagnostics, Inc. operates as a medical technology company. It develops, manufactures, and markets molecular biomarkers, medical devices, and consumables for the detection, risk assessment, and diagnosis of cancerous and precancerous conditions and related diseases. The company offers USE 33, an ultrasonic decalcification instrument that automatically runs the process under controlled temperatures; TPC 15 Duo and Trio, a tissue processing instrument; TES 99 and TES Valida cooling units; and M530, A550, M380 microtomes for tissue sectioning. It also provides M630, a freezing microtome; TST44, a robotic multi-staining system; COT 20, a linear staining system; and RCM 9000, ACS 720, and TWISTER robotic coverslippers. In addition, the company develops SoftKit device for the self-collection of a sample that can be evaluated to provide an assessment of the health of the entire female genital tract. It sells its products through direct sales and distributors in the United States, China, Europe, and North Africa. The company serves histology and cytology laboratories associated with hospitals or research institutions, and independent laboratories. Medite Cancer Diagnostics, Inc. is based in Orlando, Florida.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | -99.56% | -99.99% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Specialties: +8.3%-26.3%
-
EPS growth Medical - Specialties: +10.1%-160.0%
-
FCF margin FCF growth · Medical - Specialties: +51.3%-70.4%
-
EBIT margin Medical - Specialties: +12.6%-95.1%
-
ROIC Medical - Specialties: +6.6%-60.7%
-
Share dilution Medical - Specialties: 0.0%+23.4%
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×-0.87×
Owner Earnings
Owner's Earnings history not available.
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2018-10-15 | Lewis William Austin IV | Director / 10% Owner | P-Purchase | A | Common Stock | 8,973,333 | 0.08 | 673.0K | 36,611,163 | — | ↗ |
| 2018-07-27 | Von Rump Stephen L. | Director / Officer | P-Purchase | A | Common Stock | 133,333 | 0.08 | 10.0K | 266,666 | — | ↗ |
| 2018-07-25 | Lewis William Austin IV | Director / 10% Owner | P-Purchase | A | Common Stock | 1,100,000 | 0.08 | 82.5K | 29,771,162 | — | ↗ |
| 2018-07-09 | Lewis William Austin IV | Director / 10% Owner | P-Purchase | A | Common Stock | 400,000 | 0.08 | 30.0K | 28,671,162 | — | ↗ |
| 2018-06-28 | Lewis William Austin IV | Director / 10% Owner | P-Purchase | A | Common Stock | 1,333,334 | 0.08 | 100.0K | 21,337,830 | — | ↗ |
| 2018-05-02 | Von Rump Stephen L. | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 133,333 | — | ↗ |
| 2018-04-26 | Lewis William Austin IV | Director / 10% Owner | P-Purchase | A | Common Stock | 8,000,000 | 0.08 | 600.0K | 20,004,496 | — | ↗ |
| 2018-04-04 | FORTUNOFF GREGORY | Director | P-Purchase | A | Common Stock | 1,333,334 | 0.75 | 1.00M | 1,533,334 | — | ↗ |
| 2018-03-27 | KANTER JOEL S | Director | — | I | Warrants | 19,724 | 0.60 | 11.8K | 0 | — | ↗ |
| 2018-02-12 | Lewis William Austin IV | Director | I-Discretionary | A | Common Stock | 1,333,333 | 0.08 | 100.0K | 12,004,496 | — | ↗ |
| 2018-02-06 | Lewis William Austin IV | Director | P-Purchase | A | Common Stock | 10,666,667 | 0.08 | 800.0K | 10,671,163 | — | ↗ |
| 2018-02-04 | FORTUNOFF GREGORY | Director | P-Purchase | A | Secured Convertible Note | 100,000 | 0.08 | 7.5K | 100,000 | — | ↗ |
| 2018-01-02 | FORTUNOFF GREGORY | Director | — | D | Common Stock | 0 | 0.00 | — | 200,000 | — | ↗ |
| 2017-12-21 | FORTUNOFF GREGORY | Director | — | D | Warrant | 157,791 | 0.60 | 94.7K | 0 | — | ↗ |
| 2017-11-12 | KANTER JOEL S | Director | — | I | Common Stock | 0 | 0.00 | — | 200,000 | — | ↗ |
| 2017-09-29 | Lewis William Austin IV | Director | A-Award | A | Options | 600,000 | 0.50 | 300.0K | 912,579 | — | ↗ |
| 2017-09-27 | Lewis William Austin IV | Director | P-Purchase | A | Warrants | 312,579 | 0.50 | 156.3K | 312,579 | — | ↗ |
| 2017-06-30 | KANTER JOEL S | Director | — | I | Warrants | 100,000 | 0.50 | 50.0K | 0 | — | ↗ |
| 2017-05-17 | FORTUNOFF GREGORY | Director | — | D | Warrant | 50,000 | 0.50 | 25.0K | 0 | — | ↗ |
| 2016-02-12 | Lewis William Austin IV | Director | — | D | Common Stock | 0 | 0.00 | — | 4,496 | — | ↗ |
| 2015-12-31 | Lewis William Austin IV | Director | — | D | 15% Convertible Secured Note | 64,844 | 1.60 | 103.8K | 0 | — | ↗ |
| 2015-10-05 | Ott Michaela | Director / Officer / 10% Owner | P-Purchase | A | Common Stock, par value $0.001 per share | 156,250 | 0.00 | — | 7,500,000 | — | ↗ |
| 2015-10-05 | Ott Michael Egbert | Director / Officer / 10% Owner | P-Purchase | A | Common Stock, par value $0.001 per share | 156,250 | 0.00 | — | 7,500,000 | — | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jeffrey Rencher | Chief Marketing & Business Development Officer | 95.6K | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MDIT
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
